+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience



Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience



Internal Medicine Journal 41(4): 299-307



Diabetes therapies based on manipulation of the incretin system are now widely available, with millions of people receiving treatment. The incretin hormones, glucose-dependent insulinotropic peptide and glucagon-like peptide-1 are released from endocrine cells in the small intestinal mucosa primarily in response to oral nutrient ingestion. They have various effects, but those most relevant to metabolic dysfunction include stimulation of insulin and suppression of glucagon secretion, with resultant reduction in fasting and postprandial glucose. Incretin secretion and/or action is impaired in type 2 diabetes, leading to development of strategies aimed at redressing this abnormality. These strategies include pharmacological inhibition of dipeptidyl peptidase-4, the enzyme responsible for the short half-life of endogenous incretins, and administration of long-acting dipeptidyl peptidase-4-resistant peptides that bind to and activate the glucagon-like peptide-1 receptor. In this review, we address aspects of incretin biology and pharmacotherapy with a view to highlighting potentially clinically relevant issues and areas of basic research that may impinge on these.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053810433

Download citation: RISBibTeXText

PMID: 21299778

DOI: 10.1111/j.1445-5994.2011.02439.x


Related references

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Research and Clinical Practice 82 Suppl 2: S102-S107, 2008

Incretin-based therapies: review of current clinical trial data. American Journal of Medicine 123(3 Suppl): S28-S37, 2010

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 319-324, 2013

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. American Journal of Medicine 123(7): S2-S10, 2010

Cardiac Protection via Metabolic Modulation An Emerging Role for Incretin-Based Therapies?. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 319-324, 2012

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technology & Therapeutics 8(3): 385-396, 2006

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Journal of the American Academy of Nurse Practitioners 20 Suppl 1: 7-11, 2009

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care 36(7): 2118-2125, 2014

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clinical Therapeutics 33(5): 528-576, 2011